RAY TECHNIQUES LTD

Their core work

Ray Techniques is a Jerusalem-based SME specializing in advanced carbon-based and nano diamond materials, operating at the junction of nanotechnology, biomedical science, and industrial applications. In CARTHER, they contributed expertise in carbon nanomaterials engineered for theranostic use — materials that simultaneously enable imaging and therapeutic action, typically in oncology contexts. In PANDA, they took the lead in developing nano diamond additives commercially viable for lubricants, coatings, medical devices, and scientific instruments. Their profile is that of a materials-focused company able to translate laboratory-grade nanomaterial chemistry into both research and commercial products.

What they specialise in

How they've shifted over time

Both H2020 projects started in 2016, so there is no meaningful time-based evolution to analyze — Ray Techniques entered EU-funded research with two parallel tracks simultaneously rather than sequentially. What the data does reveal is a deliberate dual strategy: one track pursuing scientific credibility through an MSCA-RISE staff-exchange (CARTHER, biomedical), and another pursuing commercial validation through the SME Instrument Phase 1 (PANDA, industrial). Whether one track became dominant after 2016–2019 cannot be determined from available data.

With all activity concentrated in 2016 and no detectable H2020 engagement afterward, it is unclear whether Ray Techniques expanded into new EU programs, pivoted to commercial scale-up, or withdrew from EU-funded research altogether — making future collaboration prospects uncertain without direct contact.

How they like to work

Ray Techniques has experience in both roles: coordinator (PANDA) and consortium partner (CARTHER), suggesting they can adapt depending on the project type and funding instrument. Their total network of 5 partners across 3 countries over 2 projects indicates consistently small, focused consortia rather than broad multi-partner networks. This profile is typical of a niche materials SME that joins or leads partnerships based on a specific technical contribution rather than project management capacity.

Ray Techniques has worked with 5 distinct consortium partners spread across 3 countries — a compact footprint that reflects their SME scale and early-stage EU engagement. As an Israeli organization participating under Israel's H2020 association agreement, their European reach is real but geographically limited.

What sets them apart

Ray Techniques holds an unusual position as one of the few Israeli SMEs in H2020 with demonstrated expertise in both biomedical theranostic nanomaterials and industrial nano diamond additives — two markets that share the same core material science but target completely different buyers. This dual applicability makes them a potentially valuable partner for consortia that need a commercially-oriented materials company with credibility in both health-tech and advanced manufacturing contexts. Their Israeli base also opens access to a strong national nanotechnology ecosystem not commonly represented in European research consortia.

Highlights from their portfolio

• CARTHER
  The largest of their two projects (EUR 180,000, 2016–2019) and the one that placed them in a pan-European MSCA-RISE network, validating their carbon nanomaterial expertise at a research-excellence level.
• PANDA
  The only project where Ray Techniques served as coordinator, and notably funded under SME Instrument Phase 1 — a competitive, business-focused scheme that confirmed commercial viability of their nano diamond additive technology.